• TG Therapeutics recently reported Phase 1 data showing a high‑concentration subcutaneous formulation of BRIUMVI was well tolerated with no new safety concerns, supporting a quarterly at‑home dosing regimen now being tested in Phase 3 for relapsing multiple sclerosis.
• If ultimately approved, this self‑administered, quarterly anti‑CD20 option could materially reshape how BRIUMVI fits into the treatment landscape for multiple sclerosis.
• We’ll now examine how the push toward a quarterly, at‑home subcutaneous BRIUMVI could influence TG Therapeutics’ investment narrative.

AI is about to change healthcare. These 39 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.

TG Therapeutics Investment Narrative Recap

To own TG Therapeutics, you need to believe BRIUMVI can sustain its role as a key multiple sclerosis therapy while TG broadens formulations and indications around it. The new Phase 1 subcutaneous data directly supports the main near term catalyst, the Phase 3 program for quarterly at home dosing, while also partially addressing the risk that payers and patients favor self administered options over IV infusions.

In that context, the recent publication of post hoc ULTIMATE I & II data in treatment naive RMS is important, because it reinforces BRIUMVI’s efficacy profile versus teriflunomide, especially in earlier disease. Together with the positive ENHANCE single infusion results, it strengthens the clinical foundation behind TG’s push into more convenient dosing formats, which could be central to how the upcoming subcutaneous readout is received.

Yet, behind the convenience story, investors also need to be conscious of how payer pressure and future competitors could affect BRIUMVI’s pricing power and...

TG Therapeutics’ narrative projects $1.5 billion revenue and $461.7 million earnings by 2029.

Uncover how TG Therapeutics' forecasts yield a $44.43 fair value, a 11% upside to its current price.

Exploring Other Perspectives

Some of the most cautious analysts were assuming TG’s earnings could slip from about US$461.9 million to US$402.4 million by 2029, and they worry that even with promising subcutaneous data, rising costs and potential pricing pressure could still cap the payoff from BRIUMVI’s growth story.

Explore 7 other fair value estimates on TG Therapeutics - why the stock might be worth over 4x more than the current price!

Reach Your Own Conclusion

Don't just follow the ticker - dig into the data and build a conviction that's truly your own.

• A great starting point for your TG Therapeutics research is our analysis highlighting 4 key rewards and 1 important warning sign that could impact your investment decision.
• Our free TG Therapeutics research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate TG Therapeutics' overall financial health at a glance.

Ready For A Different Approach?

The market won't wait. These fast-moving stocks are hot now. Grab the list before they run:

• We've uncovered the 10 dividend fortresses yielding 5%+ that don't just survive market storms, but thrive in them.
• Rare earth metals are an input to most high-tech devices, military and defence systems and electric vehicles. The global race is on to secure supply of these critical minerals. Beat the pack to uncover the 32 best rare earth metal stocks of the very few that mine this essential strategic resource.
• Uncover the next big thing with 24 elite penny stocks that balance risk and reward.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.